deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT03902080

Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)

A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)

Sponsor: Urovant Sciences GmbH

Conditions Overactive Bladder
Interventions Placebo Vibegron
Updated 19 times since 2019 Last updated: Jul 15, 2024 Started: Mar 26, 2019 Primary completion: Jun 15, 2023 Completion: Jun 15, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Overactive Bladder, this trial is completed. The trial is conducted by Urovant Sciences GmbH and has accumulated 19 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~May 2019 – ~Jul 2019 · 2 months · monthly snapshot~Jul 2019 – ~Aug 2019 · 31 days · monthly snapshot~Aug 2019 – ~Oct 2019 · 2 months · monthly snapshot~Oct 2019 – ~Dec 2019 · 2 months · monthly snapshot~Dec 2019 – ~Mar 2020 · 3 months · monthly snapshot~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshot~Apr 2020 – ~Jul 2020 · 3 months · monthly snapshot~Jul 2020 – ~Sep 2020 · 2 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Jun 2021 · 3 months · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Feb 2022 · 5 months · monthly snapshot~Feb 2022 – ~Sep 2022 · 7 months · monthly snapshot~Sep 2022 – ~Oct 2023 · 13 months · monthly snapshot~Oct 2023 – ~Jul 2024 · 9 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 9 months · monthly snapshot

Change History

19 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Oct 2023 — Jul 2024 [monthly]

    Completed PHASE3

    Status: Recruiting → Completed

  5. Sep 2022 — Oct 2023 [monthly]

    Recruiting PHASE3

▶ Show 14 earlier versions

  1. Feb 2022 — Sep 2022 [monthly]

    Recruiting PHASE3

  2. Sep 2021 — Feb 2022 [monthly]

    Recruiting PHASE3

  3. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE3

  4. Mar 2021 — Jun 2021 [monthly]

    Recruiting PHASE3

  5. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE3

  6. Sep 2020 — Jan 2021 [monthly]

    Recruiting PHASE3

  7. Jul 2020 — Sep 2020 [monthly]

    Recruiting PHASE3

  8. Apr 2020 — Jul 2020 [monthly]

    Recruiting PHASE3

  9. Mar 2020 — Apr 2020 [monthly]

    Recruiting PHASE3

  10. Dec 2019 — Mar 2020 [monthly]

    Recruiting PHASE3

  11. Oct 2019 — Dec 2019 [monthly]

    Recruiting PHASE3

  12. Aug 2019 — Oct 2019 [monthly]

    Recruiting PHASE3

  13. Jul 2019 — Aug 2019 [monthly]

    Recruiting PHASE3

  14. May 2019 — Jul 2019 [monthly]

    Recruiting PHASE3

    First recorded

Mar 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Urovant Sciences GmbH
Data source: Urovant Sciences GmbH

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aalst, Belgium , Albany, United States , Alcorcón, Spain , Almada, Portugal , Baltimore, United States , Barcelona, Spain , Boadilla del Monte, Spain , Boston, United States , Boynton Beach, United States , Braga, Portugal and 105 more locations